Elucid Vivo provides clinical solutions based on histology & machine learning. We provide solutions for lipid rich necrotic core, atherosclerotic plaque, CTA plaque analysis, risk of heart attack, and stroke.
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $107M
Investors 2
Date | Name | Website |
02.06.2022 | BlueStone ... | bluestonev... |
- | Bioverge | ventures.b... |
Funding Rounds 2
Date | Series | Amount | Investors |
10.11.2023 | Series C | $80M | - |
23.06.2022 | Series B | $27M | - |
Mentions in press and media 6
Date | Title | Description | Source |
13.11.2023 | Elucid collects $80M for AI-powered mapping of blocked arter... | The cardiovascular imaging company Elucid has made it clear they mean to deliver on their promise of... | fiercebiot... |
10.11.2023 | Elucid Raises $80M to Drive Commercialization of AI-powered ... | What You Should Know: – Elucid, a medical technology company providing AI-powered imaging analysis ... | hitconsult... |
09.11.2023 | Elucid Raises $80M in Series C Funding | Elucid, a Boston, MA-based medical technology company, raised $80M in Series C funding. The round, ... | finsmes.co... |
24.06.2022 | Elucid clears $27M funding for heart disease diagnostic AI | No, it’s not a dream—Boston-based startup Elucid has closed its largest fundraising session yet, a f... | fiercebiot... |
23.06.2022 | Elucid Raises $27M in Series B Funding | Elucid, a Boston, MA-company developing non-invasive medical software to characterize cardiovascular... | finsmes.co... |
- | Elucid | “Elucid delivers personalized patient care with the only objective and quantitative CTA-based arteri... | fastfounde... |